Allergan Hits Watson With Patent Suit Over Combigan

By Megan Stride

Law360, New York (September 03, 2010, 11:39 AM ET) -- Allergan Inc. has launched another patent infringement suit over its Combigan eye medication, targeting Watson Pharmaceutical Inc.'s efforts to market a generic version of the glaucoma drug.

Allergen filed suit in the U.S. District Court for the Eastern District of Texas on Thursday, claiming that Watson infringed four patents when it filed an abbreviated new drug application with the U.S. Food and Drug Administration for generic Combigan.

According to the complaint, the plaintiff received a letter from Watson on July 30 saying that it had filed...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles